Loading stock data…
$73.64+1.56 (+2.16%)
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.
Monopar Therapeutics Inc. in the Healthcare sector is trading at $73.64 with a market capitalization of $768M. Wall Street consensus targets $129.92 (12 analysts), implying a +76.4% move over the next 12 months. The stock is currently 41% below its 52-week high of $124.82, remaining 4.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$6.64M↓ | -$5.23M↑ | -$6.16M↓ | -$4.09M↓ | -$3.23M |
| Net Income | -$5.31M↓ | -$3.89M↑ | -$5.20M↓ | -$3.44M↓ | -$2.45M |
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNP...